Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

8670 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-03-30

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Costa Rican Natural History Study of HPV and Cervical Neoplasia

NCT00342173

Cervical Neoplasia

TERMINATED

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

NCT00019110

Anal Cancer Cervical Cancer Esophageal Cancer +3 more

COMPLETED PHASE1

Immunogenicity and Safety Study of NBP615 in Healthy Female

NCT04453241

Cervical Cancer

COMPLETED PHASE1/PHASE2

Gardasil Vaccination as Therapy in Low Grade Cervical Abnormalities

NCT00501189

Papillomavirus Infections

WITHDRAWN

Provider-Focused Intervention for Maximizing HPV Vaccine Uptake in Young Cancer Survivors

NCT04469569

Papillomavirus Vaccines

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.

II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.

III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.

OUTLINE:

Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anal Carcinoma Cervical Carcinoma Human Papillomavirus Infection Human Papillomavirus-Related Cervical Carcinoma Oral Cavity Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Observational (long term follow-up)

Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.

Cytology Specimen Collection Procedure

Intervention Type OTHER

Correlative studies

Laboratory Biomarker Analysis

Intervention Type OTHER

Correlative studies

Long-term Follow-up

Intervention Type OTHER

Undergo extended follow-up

Questionnaire Administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cytology Specimen Collection Procedure

Correlative studies

Intervention Type OTHER

Laboratory Biomarker Analysis

Correlative studies

Intervention Type OTHER

Long-term Follow-up

Undergo extended follow-up

Intervention Type OTHER

Questionnaire Administration

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cytologic Sampling long term follow-up (clinical study) long-term follow-up (research) LTFU

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study
* Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up
* A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years
* Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule
* UNVACCINATED CONTROL GROUP:
* Born in or between July 1978 and November 1987
* Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005
* Able to speak/understand Spanish
* Apparently mentally competent
* Written informed consent obtained prior to enrollment

Exclusion Criteria

* History of cervical cancer
* History of hysterectomy
* Any important medical condition or other criteria that the investigator considers that precludes enrollment
* Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes